Article
Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2002
Einspahr Janine G, Nelson Mark A, Saboda Kathylynn, Warneke James, Bowden G Timothy, Alberts David S
Abstract excerpt
More than one million new skin cancers are diagnosed yearly in the United States creating the need for effective primary and chemopreventive strategies to reduce the incidence, morbidity, and mortality associated with skin cancer. Skin chemoprevention trials often focus on subjects at high risk of nonmelanoma skin cancers and include biological endpoints like number of actinic keratoses (AK) and measures of cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.